Kinsap Medisciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 01-01-2025
- Paid Up Capital ₹ 0.48 M
as on 01-01-2025
- Company Age 19 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.00 M
as on 01-01-2025
- Revenue 14819.32%
(FY 2022)
- Profit 12742.55%
(FY 2022)
- Ebitda 18907.63%
(FY 2022)
- Net Worth 32.39%
(FY 2022)
- Total Assets 204.63%
(FY 2022)
About Kinsap Medisciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M.
The company has closed loans amounting to ₹4.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Urmila Buchasia, Kishori Jaiswal, and Saket Jaiswal serve as directors at the Company.
- CIN/LLPIN
U24230GJ2006PTC047424
- Company No.
047424
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location69, Green Park, Gujarat
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Kinsap Medisciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saket Jaiswal  | Managing Director | 02-Jan-2006 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Urmila Buchasia | Whole-Time Director | 31-Mar-2015 | Current |
| Kishori Jaiswal | Whole-Time Director | 31-Mar-2015 | Current |
Financial Performance of Kinsap Medisciences.
Kinsap Medisciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14819.32% increase. The company also saw a substantial improvement in profitability, with a 12742.55% increase in profit. The company's net worth Soared by an impressive increase of 32.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kinsap Medisciences?
In 2022, Kinsap Medisciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 18 Oct 2006 | ₹4.00 M | Satisfied |
How Many Employees Work at Kinsap Medisciences?
Unlock and access historical data on people associated with Kinsap Medisciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kinsap Medisciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kinsap Medisciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
